TIDMAGL
Angle PLC
18 February 2021
For immediate release 18 February 2021
ANGLE plc ("the Company")
CTCS HARVESTED BY PARSORTIX UNCOVER NOVEL METASTATIC
BIOMARKER
Parsortix system able to harvest difficult-to-detect mesenchymal
CTCs
Metastatic biomarker Cyr61 found by researchers in 40% of breast
cancer CTCs may be a novel therapeutic target in treating
drug-resistant breast cancers
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that the University Medical Centre
Hamburg-Eppendorf, Germany, has published new research in the peer
reviewed journal Cancers, that demonstrates the ability of the
Parsortix(R) system to harvest circulating tumour cells (CTCs) with
a mesenchymal phenotype, which can be used to detect the metastatic
biomarker cysteine-rich angiogenetic inducer 61 (Cyr61) in breast
cancer patients.
The Cyr61 protein is a potent regulator of many cellular
functions important in cancer development, including cell
proliferation, survival/apoptosis, senescence, motility/chemotaxis,
invasion into the extracellular matrix, gene expression,
differentiation, and angiogenesis. Cyr61 is expressed in most forms
of solid tumours and in breast cancer, potentially playing a role
in tumour progression, metastatic expansion, and the development of
resistance to anti-cancer drugs including endocrine therapies.
In this study, researchers found that Cyr61 was over-expressed
in 43% of CTCs isolated from 35 breast cancer patients. In
addition, they were able to demonstrate in breast cancer cell-lines
that the loss of Cyr61 reduced the viability of tumour cells by
decreasing cancer cell proliferation and cell survival. As such,
Cyr61 might serve as a novel marker for CTCs and disseminated
tumour cells (DTCs) similar to those found in the bone marrow and
help identify cells with a more aggressive phenotype. Furthermore,
Cyr61 could represent a target for the development of novel
anti-metastatic drugs.
In the US, breast cancer is the most frequently diagnosed cancer
in women with an estimated 276,480 new cases recorded in 2020.
Despite new treatment options and advances in patient management
protocols, some 30% of women initially diagnosed with earlier
stages of breast cancer eventually develop recurrent advanced or
metastatic disease. Although the prognosis of patients with
metastatic breast cancer (MBC) has significantly improved,
metastatic disease remains largely incurable with median survival
of three years.
CTCs, as a liquid biopsy, have significant potential as a
complementary prognostic and diagnostic tool for clinicians. Access
to tumour cells from a peripheral blood sample provides
non-invasive, real-time monitoring of cancer patients, giving
insight into clonal evolution during tumour metastasis. Critically,
the analysis of CTCs from a blood sample has the potential to
provide actionable information for the approximately 50% of all MBC
patients who are unable to have a solid tissue biopsy of the
metastatic site.
This study demonstrates how CTCs can provide insight into
molecular mechanisms of cancer cell resistance and metastatic
spread, which may have potential as a novel therapeutic target in
treating drug-resistant breast cancers.
This research has been published in the peer-reviewed
publication Cancers and may be accessed via
https://angleplc.com/library/publications/ .
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This new study observed that mesenchymal DTCs are strongly
positive for PD-L1 and Cyr61 and that Cyr61/PD-L1 double-positive
DTCs may escape the immune system and establish distant metastasis.
Cyr61 might therefore serve as a novel biomarker for a subset of
CTCs and DTCs with high plasticity in breast cancer. In addition,
Cyr61 might represent an interesting anti-metastatic target that
could be explored in future studies.
Use of the Parsortix system in uncovering potential new
therapeutic targets through its ability to harvest mesenchymal as
well as epithelial CTCs for analysis provides yet further evidence
of its advantages over other liquid biopsy approaches. ANGLE's
ability to provide this actionable information should prove highly
attractive to drug developers looking for new approaches for
hard-to-treat cancers and bodes well for the forthcoming launch of
our new pharmaceutical services business. "
For further information on ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon
Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen as being an intact cell they allow
DNA, RNA and protein analysis and thus provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status. In addition, the live CTCs harvested can be cultured, which
offers the potential for testing response to drugs outside the
patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix(R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and is currently in
the process of a 200 patient clinical verification study.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD(TM) Ziplex(R)
platform and is based on a patented flow through array technology.
It provides for low cost, highly multiplexed, rapid and sensitive
capture of targets from a wide variety of sample types. A
proprietary chemistry approach (the HyCEAD method) allows for the
capture and amplification of over 100 biomarkers simultaneously in
a single reaction. The HyCEAD Ziplex system is extremely sensitive
and is ideal for measuring gene expression and other markers
directly from Parsortix harvests and was used in the ovarian cancer
pelvic mass triage test to achieve best in class accuracy (AUC-ROC)
of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
41 peer-reviewed publications and numerous publicly available
posters, available on our website.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGZGMZRNRGMZM
(END) Dow Jones Newswires
February 18, 2021 02:00 ET (07:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024